Trials / Unknown
UnknownNCT04555369
The Value of ctDNA on Chemotherapy Efficacy for mCRC
Study on the Efficacy of Chemotherapy for Metastatic Colorectal Cancer Evaluated by Circulating Tumor DNA
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to evaluate the value of ctDNA in predicting the drug efficacy of chemotherapy for metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | ct-DNA | The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy. |
Timeline
- Start date
- 2020-09-23
- Primary completion
- 2023-09-01
- Completion
- 2025-09-01
- First posted
- 2020-09-18
- Last updated
- 2021-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04555369. Inclusion in this directory is not an endorsement.